Coagulation Dysregulation
Clinical knowledge about COVID-19-associated coagulopathy, including risk factors for development and how to prevent and manage hypercoagulability and thrombosis, continue to evolve as new data emerge from studies worldwide.
In mid-February 2020, the Journal of...
Online Exclusives
CMS Proposes New Reimbursement Rate for CAR T-Cell Therapies
The Centers for Medicare and Medicaid Services (CMS) has proposed a new system for calculating reimbursement rates for hospitals administering chimeric antigen receptor (CAR)...
28 Million Elective Surgeries Worldwide Estimated to be Delayed by COVID-19
A study published in the British Journal of Surgery estimates that 28.4 million elective surgeries worldwide could be canceled or postponed in 2020 because...
News
From the Blood Journals
Daratumumab Monotherapy Produces Rapid, Deep Hematologic Responses in Light Chain Amyloidosis
In a study of previously treated patients with systemic light chain amyloidosis (AL), nearly half of patients treated with intravenous (IV) daratumumab experienced at...
Temozolomide Demonstrates High Response in Older Patients With Primary Vitreoretinal Lymphoma
Temozolomide demonstrated a high overall response rate in a study of patients with primary vitreoretinal lymphoma (PVRL) who were either considered ineligible for intensive...
Multimedia
Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL
Constantine S. Tam, MBBS, MD, discusses findings from the phase III SEQUOIA trial, in which 92% of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...
Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline...
Nearly half of patients treated with acalabrutinib plus venetoclax and obinutuzumab achieved a complete response with undetectable minimal residual disease. Benjamin L. Lampson, MD,...
David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML
Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman,...
Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis
Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears...
On Location
Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL/SLL
The availability of B-cell receptor inhibitors (BCRis) and other novel agents for the treatment of...
Early-Phase Study Shows Promising Response Rates With Venetoclax Plus Navitoclax in ALL
Nearly half of patients with relapsed/refractory acute lymphocytic leukemia (ALL) had a complete response (CR)...
Daratumumab-Based Induction and Response-Adapted Consolidation Induces MRD Negativity in Patients With Newly Diagnosed Myeloma
Induction therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) followed by autologous transplant and Dara-KRd...
Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma
Adding the antibiotic clarithromycin to lenalidomide plus dexamethasone improved the response rate in patients with...
Can Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Skip Radiation Therapy?
Results from the Intergroup National Clinical Trials Network (NCTN) study S1001 demonstrated that 89% of...
DDGP Versus SMILE: Comparing Regimens for Extranodal Natural Killer T-Cell Lymphoma
In patients with extranodal natural killer T-cell lymphoma (ENKTL), treatment with the chemotherapy regimen of...
Latest Headlines
ASH Directions
ASH Research Collaborative Data Hub Launches COVID-19 Registry for Hematology
The ASH Research Collaborative’s (ASH RC’s) Data Hub recently launched a new COVID-19 Registry for Hematology, a global registry with clinical data on people...
Nominate Yourself or a Colleague for an ASH Leadership Position, and more
Clinical Practitioners: Nominate Yourself or a Colleague for an ASH Leadership Position
American Society of Hematology (ASH) members in good standing can nominate themselves or...
CPRIT Awards $19.6 Million to MD Anderson, Sidney Kimmel Establishes Philadelphia T-cell Lymphoma/Leukemia Initiative,...
Sidney Kimmel Cancer Center at Jefferson Establishes Philadelphia T-cell Lymphoma/Leukemia Initiative
The Sidney Kimmel Cancer Center – Jefferson Health (SKCC at Jefferson) will use a...
Remembering Clara Bloomfield, City of Hope Appoints Eileen Smith as Head of Hematology, and...
Remembering Clara Bloomfield, MD (1942 – 2020)
Leukemia scientist Clara Bloomfield, MD, died on March 1, 2020 at the age of 77.
With more than 50...
David H. Koch Center Opens at MSKCC, Sidney Kimmel Welcomes Usama Gergis, and more
Patrick White Appointed Chair in Palliative Medicine and Supportive Care
Patrick White, MD, director of the Division of Palliative Medicine at Washington University School of...
Coagulation Dysregulation
Clinical knowledge about COVID-19-associated coagulopathy, including risk factors for development and how to prevent and manage hypercoagulability and thrombosis, continue to evolve as new...
Medicine and Machines
As artificial intelligence applications broaden, experts advise physicians to approach them as tools – not threats.
Tools have been invented to aid physicians and improve...
Putting Mutation Testing in Myeloid Malignancies to the Test
In 2014, the World Health Organization (WHO) convened a clinical advisory committee to begin updating and revising the existing classification of myeloid neoplasms (MPNs)...
